Trial

Subscribe to Trial via RSS

In a rare trial in a securities class action lawsuit, a federal jury has ruled that hedge fund Armistice Capital and certain of its executives had not, as the plaintiffs alleged, committed insider trading or engaged in a pump-and-dump scheme in selling over $200 million in vaccine company Vaxart stock during the COVID-19 pandemic. The jury specifically held that the plaintiffs had not proven that the defendants had engaged in a scheme to defraud and had not proven their insider trading allegations.

Continue Reading Rare Securities Class Action Lawsuit Trial Results in Defense Verdict

Following a rare trial in a federal securities class action lawsuit, a civil jury late last week found that statements Elon Musk made on social media in 2022 about his proposed $44 billion acquisition of Twitter misled investors. However, the jury also found that the plaintiff had not made the case that certain other statements by Musk were misleading. The jury’s verdict has a number of interesting implications, as discussed below. A copy of the jury’s March 20, 2026 verdict form can be found here.

Continue Reading Jury in Rare Securities Suit Trial Finds Musk Misled Twitter Investors